Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide, with limited curative treatments for many genetic and acquired forms. The CRISPR-Cas9 gene-editing system has emerged as a groundbreaking tool for precise genome modification, offering potential therapeutic strategies for conditions such as hypertrophic cardiomyopathy, familial hypercholesterolemia, and heart failure. This review examines recent preclinical and clinical advancements, delivery mechanisms, ethical considerations, and future directions for CRISPR-based cardiovascular therapies.
Cardiovascular diseases encompass a broad spectrum of disorders, including coronary artery disease (CAD), cardiomyopathies, arrhythmias, and atherosclerosis. While pharmacological and interventional treatments have improved outcomes, many CVDs—particularly those with genetic origins—remain incurable.
The CRISPR-Cas9 system enables precise DNA modifications, allowing researchers to:
Correct pathogenic mutations (e.g., in MYBPC3 for hypertrophic cardiomyopathy).
Knock out disease-promoting genes (e.g., PCSK9 for cholesterol reduction).
Enhance protective pathways (e.g., APOA1 for atherosclerosis prevention).
This review evaluates key studies, challenges, and translational potential of CRISPR-Cas9 in CVD.
CRISPR-Cas9 consists of:
Guide RNA (gRNA): Targets a specific DNA sequence.
Cas9 nuclease: Induces double-strand breaks (DSBs).
DNA repair pathways:
Non-homologous end joining (NHEJ): Disrupts gene function (e.g., knockout of PCSK9).
Homology-directed repair (HDR): Corrects mutations (e.g., fixing MYBPC3 mutations).
Recent innovations like base editing and prime editing reduce off-target risks, enhancing safety for clinical use.
Hypertrophic Cardiomyopathy (HCM):
Mutations in MYBPC3 and MYH7 lead to abnormal cardiac muscle thickening.
Study: Ma et al. (2017) used CRISPR to correct MYBPC3 mutations in human embryos, restoring normal function.
Dilated Cardiomyopathy (DCM):
CRISPR has been tested in vitro to edit TTN and LMNA mutations.
PCSK9 Knockout:
Loss-of-function PCSK9 mutations reduce LDL cholesterol.
Study: Rothgangl et al. (2021) demonstrated in vivo PCSK9 disruption in mice, lowering LDL by 50%.
APOA1 Enhancement:
Increasing HDL via APOA1 editing may reduce plaque formation.
ANGPTL3 Inhibition: Reduces triglycerides and CVD risk.
Cardiac Regeneration: Editing stem cells to improve post-MI repair.
CRISPR has corrected KCNQ1 and SCN5A mutations in cellular models.
A major hurdle for CRISPR-CVD therapies is efficient and safe delivery to cardiac tissue. Current approaches include:
Adeno-associated viruses (AAVs): Most common, but limited by immunogenicity and cargo size.
Lipid nanoparticles (LNPs): Improved for systemic delivery (e.g., PCSK9 targeting).
Ex vivo editing: Modifying patient-derived cardiomyocytes before reinfusion.
Off-target effects: Unintended genomic edits may cause cancer or dysfunction.
Germline editing: Heritable changes raise ethical debates.
Immune response: Pre-existing antibodies against Cas9 may limit efficacy.
Clinical trials: First human trials for PCSK9 and TTR amyloidosis are underway.
Epigenome editing: Silencing genes without DNA breaks (e.g., PCSK9 methylation).
CRISPR screens: Identifying novel therapeutic targets in CVD.
CRISPR-Cas9 represents a paradigm shift in cardiovascular therapeutics, with potential cures for genetic disorders and innovative approaches to acquired CVD. While challenges in delivery, specificity, and ethics remain, rapid advancements suggest clinical applications within the next decade.
✔ CRISPR can correct HCM, DCM, and familial hypercholesterolemia mutations.
✔ PCSK9 knockout mimics natural cardioprotective mutations.
✔ Delivery systems (AAVs, LNPs) are improving but need refinement.
✔ Base/prime editing may soon enable safer, more precise therapies.
Ma, H. et al. (2017). Nature. Correction of a pathogenic gene mutation in human embryos.
Rothgangl, T. et al. (2021). Nature Biotechnology. In vivo CRISPR PCSK9 editing.
Musunuru, K. (2023). Circulation. CRISPR and cardiovascular diseas
